Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral recombinant ovine interferon-tau for relapsing-remitting multiple sclerosis
ACTRN12606000241538Phase 2Terminated
- Sponsor
- PepGen
- Start
- Jul 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ovine interferon tau in multiple sclerosis (MS) (4 arms), sponsored by PepGen. Primary endpoint: Number of new Gadolinium-enhanced lesions on MRI. Started Jul 2006; status: terminated.
02
Drugs
ovine interferon tau
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12606000241538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000241538.